Kamal Puri is the Chief Scientific Officer at OncoResponse Inc. He has over 25 years of R&D experience in immunology, oncology, and neurobiology. Kamal joined OncoResponse from Celgene, where he led efforts for immunology discovery. Prior to Celgene, he was at Gilead and contributed to the approval of Zydelig™ for the treatment of hematological malignancies, and directed research efforts on multiple discovery projects in inflammation and Oncology. Prior to Gilead, Kamal was Head of Research at Calistoga Pharma, where he was responsible for a wide range of activities with success in advancing several drug candidates into clinical development for multiple indications. Kamal was trained with Prof. Timothy Springer at Harvard University.